Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
In contrast, a cost-effectiveness analysis in the UK reported that once-weekly treatment with 1 mg subcutaneous semaglutide was cost-effective from a healthcare payer perspective, compared with 25 mg empagliflozin for patients with T2D for whom metformin monotherapy provided inadequate glycemic control [23]
It was originally developed for the treatment of type 2 diabetes and has also shown significant effects on weight loss
It targets the satiety centers of the brain
For individuals with genuine clinical need such as those with obesity-related comorbidities or HIV-associated lipodystrophy referral to a specialist service is appropriate
